AI Article Synopsis
- The article initially had a spelling mistake in the author's name, listing it as Jonah Sacha instead of Jonah B Sacha.
- The error has now been fixed in both the PDF and HTML formats of the article.
- All published versions of the article should now reflect the correct spelling of the author's name.
Article Abstract
The original version of this Article contained an error in the spelling of the author Jonah B Sacha, which was incorrectly given as Jonah Sacha. These errors have now been corrected in both the PDF and HTML versions of the Article.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232182 | PMC |
| http://dx.doi.org/10.1038/s41467-018-07304-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequence Analysis of microRNAs Encoded by Simian Lymphocryptoviruses.
Viruses
December 2024
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Lymphocryptoviruses (LCVs) are ubiquitous gamma-herpesviruses that establish life-long infections in both humans and non-human primates (NHPs). In immunocompromised hosts, LCV infections are commonly associated with B cell disorders and malignancies such as lymphoma. In this study, we evaluated simian LCV-encoded small microRNAs (miRNAs) present in lymphoblastoid cell lines (LCLs) derived from a Mauritian cynomolgus macaque () with cyLCV-associated post-transplant lymphoproliferative disease (PTLD) as well as the viral miRNAs expressed in a baboon () LCL that harbors CeHV12.
View Article and Find Full Text PDFA model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques.
PLoS Pathog
November 2024
Oregon National Primate Research Center; Oregon Health & Science University; Beaverton, Oregon, United States of America.
Immunocompromised individuals are at risk for developing lymphocryptovirus-associated lymphoproliferative diseases, such as Epstein Barr virus (EBV)-associated B cell lymphomas and post-transplant lymphoproliferative disorder (PTLD). We previously reported development of cynomolgus lymphocryptovirus (CyLCV)-associated PTLD in Mauritian cynomolgus macaques (MCMs) undergoing hematopoietic stem cell transplantation (HSCT), which mirrored EBV-PTLD in transplant patients. Here, we sought to develop a MCM model of lymphocryptovirus-associated lymphoproliferative disease in immunosuppressed MCMs without HSCT.
View Article and Find Full Text PDFStem cell transplantation and allogeneic immunity: post treatment control or HIV cure?
Curr Opin HIV AIDS
January 2025
Division of Pathobiology and Immunology, Oregon National Primate Research Center.
Purpose Of Review: Long-lasting HIV remission has been reported in a small group of people with HIV (PWH) following allogenic hematopoietic stem cell transplants (HSCT) for the treatment of hematologic malignancies. While the mechanisms of HIV remission following release from antiretroviral therapy (ART) were not initially known, subsequent findings from clinical cases and preclinical nonhuman primate studies have implicated mechanisms of clearance. Here, we review the six currently published human cases of long-term ART-free HIV remission.
View Article and Find Full Text PDFHuman cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8 T cells.
Sci Immunol
October 2024
Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Article Synopsis
- Rhesus cytomegalovirus (RhCMV) vectors help control simian immunodeficiency virus (SIV) by activating CD8 T cells that are restricted by major histocompatibility complex (MHC)-E.
- The effectiveness of these responses relies on the deletion of eight specific RhCMV gene sequences that are also found in human cytomegalovirus (HCMV).
- HCMV's UL18 gene inhibits unconventional T cell activation by binding to an receptor (LIR-1), so removing this binding ability from the HCMV genes in vaccines could enhance the induction of protective MHC-E-restricted T cells.
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.
Clin Ther
November 2024
Quest Clinical Research, San Francisco, California. Electronic address:
Purpose: Early in the course of the SARS-CoV-2 pandemic it was hypothesised that host genetics played a role in the pathophysiology of COVID-19 including a suggestion that the CCR5-Δ32 mutation may be protective in SARS-CoV-2 infection. Leronlimab is an investigational CCR5-specific humanized IgG4 monoclonal antibody currently in development for HIV-1 infection. We aimed to explore the impact of leronlimab on the severity of disease symptoms among participants with mild-to-moderate COVID-19.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!